Givinostat - Emerging Insight and Market Forecast Report to 2030 - ResearchAndMarkets.com

DUBLIN--()--The "Givinostat - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

The report provides comprehensive insights about an investigational product for Duchenne Muscular Dystrophy in 7 Major Markets. A detailed picture of the Givinostat in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product.

The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Givinostat is being developed by Italfarmaco in phase III stage of development for the treatment of Duchenne Muscular Dystrophy. Givinostat, is an HDAC inhibitor (HDACi, a principle candidate, currently being developed for the treatment of DMD. Since Givinostat acts on the pathogenetic events downstream of the genetic defects, it is potentially a treatment for the whole DMD population and to counter the disease pathogenetic events in all muscular districts. The FDA has granted Givinostat Orphan Drug, and Fast Track designations for the treatment of DMD. The European Commission has granted Orphan Medicinal Product designation for Givinostat for the treatment of DMD.

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around Givinostat.
  • The report contains forecasted sales for Givinostat till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Duchenne Muscular Dystrophy.
  • The report also features the SWOT analysis with analyst insights and key findings of Givinostat.

Report Highlights

  • In the coming years, the market scenario for Duchenne Muscular Dystrophy is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Givinostat dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Duchenne Muscular Dystrophy are giving market competition to Givinostat and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of Givinostat.
  • Our in-depth analysis of the forecasted sales data of Givinostat from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Givinostat.

Key Questions Answered

  1. Which company is developing Givinostat along with the phase of the clinical study?
  2. What is the technology utilized in the development of Givinostat?
  3. What is the product type, route of administration and mechanism of action of Givinostat?
  4. What is the clinical trial status of the study and study completion date?
  5. What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Givinostat development?
  6. What are the key designations that have been granted to Givinostat?
  7. What is the forecasted market scenario of Givinostat?
  8. What is the history of Givinostat and what is its future?
  9. What is the forecasted sales of Givinostat in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  10. What are the other emerging products available and how these are giving competition to Givinostat?
  11. Which are the late-stage emerging therapies under development for the treatment of the Duchenne Muscular Dystrophy?

Key Topics Covered:

1. Drug Overview

1.1. Product Detail

1.2. Mechanism of Action

1.3. Dosage and Administration

1.4. Research and development activity

1.4.1. Clinical Development

1.4.2. Safety and Efficacy

1.5. Other Development Activities

2. Market Assessment

2.1. 7MM Market Analysis

2.2. The United States Market

2.3. Germany Market

2.4. France Market

2.5. Italy Market

2.6. Spain Market

2.7. United Kingdom Market

2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

Companies Mentioned

  • Italfarmaco

For more information about this report visit https://www.researchandmarkets.com/r/36pqjs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900